Impact of antiretroviral drugs on the microbiome: Unknown answers to important questions

Sandra Pinto-Cardoso, Nichole Klatt, Gustavo Reyes-Terán

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of review Little is known on how different antiretroviral (ARV) drugs affect the gut microbiome in HIV infection; and conflicting data exists on the effect of ARV drugs on residual inflammation/immune activation and microbial translocation. Recent findings Gut microbiome involvement in the transmission and pathogenesis of HIV infection is increasingly being recognized. Various studies have shown that antiretroviral therapy (ART) is unable to restore gut health despite effective suppression of plasma HIV viremia. Indeed, the resolution of residual inflammation and gut microbial translocation is partial under ART. Very recent studies have provided new evidence that ARV combinations can differentially affect the gut microbiome, immune activation and microbial translocation. Furthermore, a recent article uncovered a link between drug metabolism and specific microbial species indicating that microbes can directly metabolically degrade ARV drugs when administered topically. Summary There are still many unanswered questions regarding ARVs and the gut microbiome. It is, therefore, critical for researchers to address the effect of distinct ARV drugs on the microbiome and vice versa: The effects of the microbiome on ARV drug metabolism, and speculate about possible therapeutic avenues.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalCurrent Opinion in HIV and AIDS
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Microbiota
Pharmaceutical Preparations
HIV Infections
Inflammation
Viremia
Therapeutics
Research Personnel
HIV
Gastrointestinal Microbiome
Health

Keywords

  • antimicrobial properties
  • antiretroviral drugs
  • butyrate-producing bacteria
  • gut microbiome
  • microbial dysbiosis

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology

Cite this

Impact of antiretroviral drugs on the microbiome : Unknown answers to important questions. / Pinto-Cardoso, Sandra; Klatt, Nichole; Reyes-Terán, Gustavo.

In: Current Opinion in HIV and AIDS, Vol. 13, No. 1, 01.01.2018, p. 53-60.

Research output: Contribution to journalReview article

@article{79119bbd87964334a96ad01e51ec743e,
title = "Impact of antiretroviral drugs on the microbiome: Unknown answers to important questions",
abstract = "Purpose of review Little is known on how different antiretroviral (ARV) drugs affect the gut microbiome in HIV infection; and conflicting data exists on the effect of ARV drugs on residual inflammation/immune activation and microbial translocation. Recent findings Gut microbiome involvement in the transmission and pathogenesis of HIV infection is increasingly being recognized. Various studies have shown that antiretroviral therapy (ART) is unable to restore gut health despite effective suppression of plasma HIV viremia. Indeed, the resolution of residual inflammation and gut microbial translocation is partial under ART. Very recent studies have provided new evidence that ARV combinations can differentially affect the gut microbiome, immune activation and microbial translocation. Furthermore, a recent article uncovered a link between drug metabolism and specific microbial species indicating that microbes can directly metabolically degrade ARV drugs when administered topically. Summary There are still many unanswered questions regarding ARVs and the gut microbiome. It is, therefore, critical for researchers to address the effect of distinct ARV drugs on the microbiome and vice versa: The effects of the microbiome on ARV drug metabolism, and speculate about possible therapeutic avenues.",
keywords = "antimicrobial properties, antiretroviral drugs, butyrate-producing bacteria, gut microbiome, microbial dysbiosis",
author = "Sandra Pinto-Cardoso and Nichole Klatt and Gustavo Reyes-Ter{\'a}n",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/COH.0000000000000428",
language = "English (US)",
volume = "13",
pages = "53--60",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Impact of antiretroviral drugs on the microbiome

T2 - Unknown answers to important questions

AU - Pinto-Cardoso, Sandra

AU - Klatt, Nichole

AU - Reyes-Terán, Gustavo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of review Little is known on how different antiretroviral (ARV) drugs affect the gut microbiome in HIV infection; and conflicting data exists on the effect of ARV drugs on residual inflammation/immune activation and microbial translocation. Recent findings Gut microbiome involvement in the transmission and pathogenesis of HIV infection is increasingly being recognized. Various studies have shown that antiretroviral therapy (ART) is unable to restore gut health despite effective suppression of plasma HIV viremia. Indeed, the resolution of residual inflammation and gut microbial translocation is partial under ART. Very recent studies have provided new evidence that ARV combinations can differentially affect the gut microbiome, immune activation and microbial translocation. Furthermore, a recent article uncovered a link between drug metabolism and specific microbial species indicating that microbes can directly metabolically degrade ARV drugs when administered topically. Summary There are still many unanswered questions regarding ARVs and the gut microbiome. It is, therefore, critical for researchers to address the effect of distinct ARV drugs on the microbiome and vice versa: The effects of the microbiome on ARV drug metabolism, and speculate about possible therapeutic avenues.

AB - Purpose of review Little is known on how different antiretroviral (ARV) drugs affect the gut microbiome in HIV infection; and conflicting data exists on the effect of ARV drugs on residual inflammation/immune activation and microbial translocation. Recent findings Gut microbiome involvement in the transmission and pathogenesis of HIV infection is increasingly being recognized. Various studies have shown that antiretroviral therapy (ART) is unable to restore gut health despite effective suppression of plasma HIV viremia. Indeed, the resolution of residual inflammation and gut microbial translocation is partial under ART. Very recent studies have provided new evidence that ARV combinations can differentially affect the gut microbiome, immune activation and microbial translocation. Furthermore, a recent article uncovered a link between drug metabolism and specific microbial species indicating that microbes can directly metabolically degrade ARV drugs when administered topically. Summary There are still many unanswered questions regarding ARVs and the gut microbiome. It is, therefore, critical for researchers to address the effect of distinct ARV drugs on the microbiome and vice versa: The effects of the microbiome on ARV drug metabolism, and speculate about possible therapeutic avenues.

KW - antimicrobial properties

KW - antiretroviral drugs

KW - butyrate-producing bacteria

KW - gut microbiome

KW - microbial dysbiosis

UR - http://www.scopus.com/inward/record.url?scp=85036645894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036645894&partnerID=8YFLogxK

U2 - 10.1097/COH.0000000000000428

DO - 10.1097/COH.0000000000000428

M3 - Review article

C2 - 29028667

AN - SCOPUS:85036645894

VL - 13

SP - 53

EP - 60

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 1

ER -